Novel natural inhibitors targeting B-RAF(V600E) by computational study

Area of Science:

• Computational chemistry
• Drug discovery
• Molecular modeling

Background:

• B-RAF (V600E) is a key target in cancer therapy.
• Identifying novel inhibitors is crucial for developing new treatments.
• Existing drugs like Vemurafenib have limitations.

Purpose of the Study:

• To screen the ZINC15 database for potential B-RAF (V600E) inhibitors.
• To identify novel lead compounds and drug candidates.
• To evaluate their binding affinity, stability, and safety profiles.

Main Methods:

• Structure-based virtual screening using LibDock and CDOCKER.
• ADME (absorption, distribution, metabolism, excretion) and toxicity predictions.
• Molecular dynamics simulations to assess complex stability.

Main Results:

• Two natural compounds (ZINC000100168592 and ZINC000049784088) were identified.
• These compounds showed superior binding energy compared to Vemurafenib.
• Predicted favorable safety profiles, including reduced mutagenicity and toxicity.

Conclusions:

• ZINC000100168592 and ZINC000049784088 are promising lead compounds for B-RAF (V600E) inhibition.
• These findings support further development for cancer medication design.
• The study contributes to the understanding of B-RAF (V600E) targeted therapies.